ArticleBMC infectious diseases2025
Willingness of receiving preventive treatment and its determinants among individuals with latent tuberculosis infection in Shenzhen, China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analysis of the current status and influencing factors of latent tuberculosis infection among new students in Taishan District in 2025.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe study aimed to assess the willingness of receiving tuberculosis preventive treatment (TPT) and identify influence factors on their decisions among individuals with latent tuberculosis infection (LTBI).
methodsIndividuals diagnosed with LTBI at a designated tuberculosis (TB) hospital were recruited from July 2023 to June 2024. Data on socio-demographic characteristics, knowledge of TB, the decision to receive TPT along with the underlying reasons were collected using electronic questionnaires. Binary logistic regression analysis was employed to identify independent factors associated with the willingness of receiving TPT. A P value less than 0.05 was considered statistically significant.
resultsA total of 317 individuals with LTBI were included in this study. Among them, 254 (80.13%) expressed a willingness to receive TPT, while 63 declined. Of those 254, 58 (22.83%) ultimately refused treatment. Gender (P < 0.05; OR = 1.983; 95% CI:1.052-3.738), educational level (P < 0.01; OR = 3.489; 95% CI:1.524-7.985) and knowledge of TB (P < 0.05; OR = 3.688; 95% CI:1.835-16.278) were significantly associated with willingness to receive TPT. The top three reasons for willingness to receive TPT were: concern about developing active tuberculosis (ATB), reducing the risk and severity of ATB, and doctor's recommendation, accounting for 69.09%, 46.69%, and 42.90%, respectively. The top four reasons for refusal TPT included: fear of adverse drug reactions, perceived low risk of developing ATB, fear of adverse drug events and uncertainty about the effectiveness of TPT, accounting for 9.46%, 6.94%, 4.73%, and 4.73%, respectively.
conclusionsTPT acceptance remained suboptimal and was influenced by gender, education level and TB knowledge. Improving LTBI patient and health care provider education on TB risks and TPT benefits could enhance adherence. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.